Merck Partners with Phanes Therapeutics to Accelerate Development of Bispecific Antibody for Solid Tumor Treatment

Shanghai, July 25, 2019 /PRNewswire/ -- A global leading technology companyMerck[Company Name] and Phanes Therapeutics, Inc. announced on July 24 that the two parties have formally signed a memorandum of cooperation to establish a close partnership for the development and manufacturing of biologics for the treatment of solid tumors.

“China is a key market for Merck. We are seeing sustained growth in demand for end-to-end bioprocess development professional services in this market,” said Udit Batra, Member of the Executive Board of Merck and CEO of Life Science. “We look forward to leveraging our collaboration to help Phanes Therapeutics accelerate the development and commercialization of novel therapies.”

Under this collaboration agreement, Merck will provide Phanes Therapeutics with BioReliance® End-to-End biologics development solutions, covering services from cell line development and process development to GMP manufacturing and commercialization. This includes the development and production of a bispecific antibody derived from Phanes Therapeutics’ proprietary bispecific antibody platform, which can simultaneously bind to two different targets or antigens on cancer cells for the treatment of solid tumors.

Leveraging over 30 years of global process development experience and a network of technical experts, Merck’s End-to-End bioprocess development team in Shanghai will work closely with global experts to ensure the rapid and efficient execution of projects. Merck’s BioReliance® End-to-End bioprocess development solutions will consistently help biopharmaceutical companies address critical challenges encountered at every stage, from molecule development to commercialization.

“As an innovative drug development company with a robust R&D pipeline, we are seeking trusted, excellent partners who possess first-class problem-solving capabilities and can help us accelerate the development of high-quality molecules,” said Dr. Minghan Wang, President and CEO of Phanes Therapeutics. “We are thrilled to collaborate with Merck to advance our pharmaceutical research (chemistry, manufacturing, and controls) for innovative drugs. Merck has extensive experience and an outstanding track record in helping global clients deliver high-quality preclinical development and clinical sample production. This collaboration will allow us to further leverage Merck’s strong global technical expertise and excellent quality systems, enabling us to continue focusing on our area of strength—achieving innovation through research. We look forward to a productive partnership with Merck in the future.”

Merck collaborates closely with biopharmaceutical customers in global clinical drug development and the scaled-up manufacturing of locally developed drugs. Furthermore, Merck boasts extensive and long-standing expertise in helping customers design facilities and comprehensive manufacturing processes. Whether at customer production sites or at Merck’s End-to-End Bioprocess Development Centers in Martillac, France; Burlington, Massachusetts, USA; and Shanghai, China, Merck is well-positioned to help customers achieve their goals.

Via social mediaTwitter @Merckgroup、Facebook @MerckGroup andLinkedIn Stay updated on Merck's latest developments.